3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
75
HER2-positive Breast Cancer
10
Neoplasms
8
Neoplasm Metastasis
4
Colonic Neoplasms
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Prostatic Neoplasms
3
Multiple Myeloma
3
Hematologic Neoplasms
3
Endometrial Neoplasms
3
Brain Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Urinary Bladder Neoplasms
2
Salivary Gland Neoplasms
2
Rectal Neoplasms
2
Pathologic Complete Response
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Inflammatory Breast Neoplasms
2
HER2-positive Early Breast Cancer
2
Colorectal Neoplasms
2
Breast Diseases
2
Biliary Tract Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Interventions
pembrolizumab
2
atezolizumab
2
Paclitaxel
2
Carboplatin
2
veliparib
1
sintilimab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
entrectinib
1
cobimetinib
1
alectinib
1
Whole Genome Sequencing
1
Vemurafenib
1
Transurethral Resection of Prostate
1
Taxes
1
Surveys and Questionnaires
1
Specimen Handling
1
Sequence Analysis, RNA
1
Radiosurgery
1
Magnetic Resonance Spectroscopy
1
HhAntag691
1
Genetic Testing
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Erlotinib Hydrochloride
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Unknown Primary
×
pertuzumab
×
1 year
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts